Drugs / Sinovac PCV24
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06800261 | May 2025 → Jun 2026 overdue | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07300644 | Nov 2025 → Sep 2026 expected | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinovac PCV24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300644 ↗ |
| Known as | PCV24 | “A phase 2 clinical trial of the study of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted...” NCT07300644 ↗1“A phase 1b clinical trial of the study of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted...” NCT06800261 ↗ |
| Modality | Vaccine | “24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd” NCT06800261 ↗ |
| Route | Intramuscular | “Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.” NCT06800261 ↗ |